SOSV

SOSV, established in 1995 and headquartered in Princeton, New Jersey, is a global venture capital firm specializing in early-stage investments. It focuses on deep tech innovations in the health and environmental sectors, supporting founders with breakthrough technologies through its HAX and IndieBio startup development programs. SOSV provides resources, facilities, and lab equipment to accelerate product development and scale, with a track record of helping its portfolio companies secure subsequent funding rounds led by top-tier investors.

Hugh Bowen

Associate

Weichang Ge

Analyst

Bradford Higgins

Venture Partner

Katie Hoffman

General Partner

Mohan Iyer

General Partner

Benjamin Joffe

Partner

Ji Ke

Partner

Stephen McCann

CFO and General Partner

Carthach McCarthy

CFO

Paul Monaghan

Principal

Brian Murphy

Finance Director

Eric Ramsay

Analyst

Sabriya Stukes Ph.D

Partner

Past deals in Medical Devices

Vision IV

Seed Round in 2025
Vision IV develops, produces diamond integrated anvil to evaluate, change and synthesize the properties of susbstances under high pressure.

InnSight Technology

Seed Round in 2025
InnSight Technology is a biotechnology company focused on enhancing diagnostics and evaluation of eye diseases. The company develops innovative ophthalmic devices, including a novel hand-held biosensor designed for the detection of anterior ophthalmic injuries. Additionally, InnSight Technology works on advanced nanotechnology-based medical devices aimed at addressing specific clinical needs in ophthalmology. By providing these tools, the company seeks to improve ocular care for clinicians and their patients.

Sharper Sense

Seed Round in 2025
Sharper Sense is a company focused on wearable neurotechnology designed to enhance sensory acuity, including vision, hearing, and touch. The firm has developed a neuromodulation patch that employs comfortable, noninvasive electrical stimulation to improve sensory processing. This technology has both clinical and commercial applications, particularly in treating sensory processing disorders and sensory loss. By enhancing performance and safety, Sharper Sense aims to provide users with a clearer and more accurate perception of their surroundings.

Ostoform

Convertible Note in 2025
Ostoform Limited is a medical device company based in Dublin, Ireland, focused on improving skin health for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform develops patented technologies aimed at managing and reducing skin complications associated with ostomies. The company's primary products include a mouldable seal that fits securely around the stoma and FLOWASSIST, which directs stoma output away from the skin. By effectively guiding the corrosive output into the ostomy bag, these products help prevent skin irritation and swelling, enhancing patient comfort and quality of life. Ostoform aims to become a global leader in the ostomy skin health market, leveraging its innovative solutions to address the needs of ostomy patients.

BioSapien

Seed Round in 2024
BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Macheon

Seed Round in 2024
Macheon AI is a robotics company specializing in the manufacture of surgical robots for head and neck procedures. These robots incorporate real-time, AI-driven decision support, aiming to enhance surgical precision, safety, and efficiency.

OLI

Seed Round in 2024
Medical Devices, Kidney Disease, Wearables, Medtech, Hardtech

ViAn Therapeutics

Seed Round in 2024
VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Flore by Sun Genomics

Convertible Note in 2024
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Minutia

Seed Round in 2024
Minutia is focused on developing innovative solutions for Type 1 Diabetes through stem cell-derived transplants that incorporate nanosensors. The company specializes in creating subcutaneous insulin-producing cell transplants that are immune-evasive and capable of real-time monitoring via proprietary cell-based sensors. This approach aims to address common challenges associated with transplants and seeks to provide a functional cure for diabetes. By advancing both transplantation techniques and monitoring capabilities, Minutia aspires to transform the clinical landscape of diabetes management and cell replacement therapies.

Bloomlife

Series B in 2024
Bloomlife is a women's health company focused on addressing critical challenges in maternal health through an innovative remote care platform. By integrating connected devices with cloud-based data analytics, Bloomlife enhances access to care and empowers expectant mothers while providing clinicians with essential information to better screen and manage pregnancy complications. The company's prenatal wearable technology is designed to assess fetal health, enabling the identification of potential complications that could lead to serious outcomes such as brain damage or stillbirth. This approach marks a significant departure from traditional methods of managing high-risk pregnancies, which often involve frequent in-person appointments and lengthy referral processes. Bloomlife aims to be a leader in remote maternal care, facilitating timely interventions and support for women, regardless of geographic barriers.

Medical Devices Corner

Pre Seed Round in 2024
Medical Devices Corner is a company focused on developing innovative medical devices aimed at enhancing cancer diagnosis and treatment. Their primary offering is a novel robotic system designed to facilitate minimally invasive surgeries. By advancing device technology, the company supports healthcare professionals in performing procedures that include biopsies and ablations with reduced invasiveness. Through its commitment to improving surgical techniques, Medical Devices Corner plays a crucial role in the health industry, striving to enhance patient outcomes and streamline medical processes.

ZiO Health

Convertible Note in 2024
ZiO Health is a biotechnology company that focuses on transforming laboratory testing through its proprietary pocket-sized technology, which allows for point-of-care diagnostics. By combining advanced biosensor technology with machine learning algorithms, ZiO Health provides real-time testing results tailored to each patient's unique profile. This innovative approach enables users to measure, test, and detect the molecular composition of various substances, facilitating personalized health insights. The company's devices aim to optimize health management and enhance patient outcomes, allowing individuals to conduct quality home diagnostics and take proactive steps in preventing illness.

Zhenshi Medical

Convertible Note in 2024
Zhenshi Medical is a medical device company that specializes in lung puncture medical robots for diagnosing and treating lung cancer.

CroíValve

Series B in 2024
CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

DeepSpin

Convertible Note in 2024
DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in developing artificial intelligence-powered magnetic resonance imaging (MRI) equipment. The company’s innovative technology aims to provide MRI imaging systems that are significantly smaller, lighter, and more cost-effective than traditional models. By leveraging generative topological design and deep learning techniques, DeepSpin's MRI machines enhance accessibility to medical imaging, making it available to a wider range of patients globally. This approach seeks to improve healthcare standards in various medical fields previously lacking adequate imaging solutions.

Kegg

Series A in 2024
Kegg is a fertility tracking device that combines the functions of monitoring vaginal fluid and facilitating pelvic floor exercises. Founded in 2017 and based in San Francisco, California, Kegg utilizes advanced sensing technology to detect changes in cervical fluid, thereby enabling women to identify their fertile window and ovulation up to seven days in advance. This innovative approach provides essential data that enhances the diagnosis, monitoring, and treatment of women's reproductive health, significantly increasing the chances of natural conception. By offering an intuitive and effective solution, Kegg empowers women with the information they need to make informed decisions regarding their fertility.

ViAn Therapeutics

Seed Round in 2024
VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

OncoPrecision

Convertible Note in 2024
OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

FeetMe

Series B in 2024
FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

VisusNano

Seed Round in 2024
VisusNano Ltd. is a pre-clinical company based in London, United Kingdom, focused on developing a drug-eluting intraocular lens implant for cataract surgery. Founded in 2016, the company aims to enhance patient outcomes by reducing the risks associated with cataract procedures, such as intraocular inflammation, infection, and opacification. This innovative lens technology eliminates the need for postoperative eye drops and laser treatments, positioning it as a potential game-changer in both human and veterinary cataract surgery markets. Through its advancements, VisusNano seeks to revolutionize the standard of care in ophthalmic procedures.

Lief Therapeutics

Seed Round in 2024
Lief Therapeutics is a medical device company focused on improving at-home care for individuals suffering from post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet biosensing patch that measures heart rate and breathing patterns with medical accuracy. This wearable device, known as Lief, helps users manage their stress responses through biofeedback exercises, allowing them to monitor their emotions and behaviors in real-time. Additionally, the device provides clinicians with insights into patient progress, enabling in-session training and tracking of psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, facilitating the tracking of daily progress and personalized practice exercises. Founded in 2014 and based in San Francisco, California, the company sells its products online.

CroíValve

Series B in 2024
CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Strados Labs

Convertible Note in 2024
Strados Labs, LLC is a medical technology company based in Philadelphia, Pennsylvania, that focuses on innovating respiratory health management through advanced biosensors and artificial intelligence. Founded in 2016, Strados Labs develops a wearable device that provides real-time insights into respiratory metrics such as breathing speed, sounds, and patterns. This device is equipped with a continuous breathing sensor that enables remote monitoring of patients with respiratory conditions like asthma and chronic obstructive pulmonary disease. By connecting the device to a mobile application, patients and healthcare providers can access critical respiratory data, facilitating informed decision-making and improved management of respiratory health.

XN Health

Convertible Note in 2024
XN Health is a medical device company based in Texas, founded in 2021. The company specializes in developing healthcare devices aimed at improving the process of mechanical ventilation. Its innovative technology focuses on phrenic nerve stimulation, which induces diaphragm contractions during ventilation. This approach helps protect against diaphragm dysfunction in patients who are mechanically ventilated, ultimately enabling them to wean off the ventilator more quickly and safely.

Feel Therapeutics

Venture Round in 2024
Feel Therapeutics is a digital precision medicine company focused on improving mental health through objective data and passive monitoring. It develops physiological and digital biomarkers alongside therapeutics that aid in the diagnosis, management, and care of mental health conditions. The company's platform includes proprietary medical-grade wearables, such as a wristband equipped with five embedded sensors, which collect biometric data. This data is analyzed using advanced computational methods to create digital biomarkers. By integrating these technologies, Feel Therapeutics aims to provide users with evidence-based insights that enhance their mental well-being and foster the development of lasting positive emotional habits.

Chronus Health

Convertible Note in 2024
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

3DK Tech

Seed Round in 2023
3DK Tech, located at HAX, specializes in advanced metal 3D printing technology aimed at enhancing manufacturing processes for various industries, including aerospace, medical, and automotive. The company has developed a proprietary method that improves the selective laser melting (SLM) process, allowing for the production of complex parts with exceptional precision and efficiency. This innovation offers significant advantages, delivering parts that are 200 times more durable, produced 10 times faster, and at a cost 10 times more effective than traditional manufacturing methods. By focusing on aviation maintenance, repair, and operations (MRO), 3DK Tech provides businesses with the ability to create high-quality components that meet rigorous industry standards.

Flore by Sun Genomics

Series B in 2023
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Lura Health

Seed Round in 2023
Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Optimize Health

Series B in 2023
Optimize Health is a digital healthcare provider specializing in remote patient monitoring (RPM) solutions. The company offers a user-friendly platform that incorporates both equipment and software designed to streamline the implementation of RPM programs. Its software aids healthcare providers in complying with Medicare billing requirements for RPM services while ensuring a positive experience for both patients and providers. The platform automatically tracks medication doses and sends reminders to users, leveraging Bluetooth technology to sync with smartphones and tablets. This approach empowers patients to manage their health effectively and enables physicians to achieve profitability from RPM services starting in the first month.

FluidAI

Series A in 2023
FluidAI Medical is a company dedicated to enhancing patient care through innovative technology in post-operative recovery. It has developed a smart catheter system that employs artificial intelligence to monitor patients' health data within the body. This proactive approach enables the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. By leveraging data-driven insights, FluidAI aims to improve recovery outcomes and transform the standards of post-operative care.

RizLab Health

Convertible Note in 2023
Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

BioAesthetics

Convertible Note in 2023
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

OLI

Seed Round in 2023
Medical Devices, Kidney Disease, Wearables, Medtech, Hardtech

QuantumCyte

Series A in 2023
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Feel Therapeutics

Convertible Note in 2023
Feel Therapeutics is a digital precision medicine company focused on improving mental health through objective data and passive monitoring. It develops physiological and digital biomarkers alongside therapeutics that aid in the diagnosis, management, and care of mental health conditions. The company's platform includes proprietary medical-grade wearables, such as a wristband equipped with five embedded sensors, which collect biometric data. This data is analyzed using advanced computational methods to create digital biomarkers. By integrating these technologies, Feel Therapeutics aims to provide users with evidence-based insights that enhance their mental well-being and foster the development of lasting positive emotional habits.

BioSapien

Convertible Note in 2023
BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

CroíValve

Series A in 2023
CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Artyc

Series A in 2023
Artyc specializes in providing sustainable cold shipping solutions for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers designed to decarbonize the cold chain, thereby fostering a more sustainable logistics industry. By utilizing these innovative containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring throughout their logistics operations, ensuring the safe and efficient transport of temperature-sensitive goods.

ViAn Therapeutics

Seed Round in 2023
VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Optimize Health

Series B in 2023
Optimize Health is a digital healthcare provider specializing in remote patient monitoring (RPM) solutions. The company offers a user-friendly platform that incorporates both equipment and software designed to streamline the implementation of RPM programs. Its software aids healthcare providers in complying with Medicare billing requirements for RPM services while ensuring a positive experience for both patients and providers. The platform automatically tracks medication doses and sends reminders to users, leveraging Bluetooth technology to sync with smartphones and tablets. This approach empowers patients to manage their health effectively and enables physicians to achieve profitability from RPM services starting in the first month.

Leadoptik

Seed Round in 2023
Leadoptik is a deep-tech company focused on developing advanced miniature imaging technology designed for minimally invasive medical procedures. Its platform enhances surgical capabilities by providing high-resolution imaging and 3D navigation in real time, allowing surgeons to visualize small anatomical structures with greater clarity than existing imaging systems. This innovative approach facilitates the early detection of cancer and improves the overall effectiveness of surgical interventions, ultimately contributing to better patient outcomes.

Medical Devices Corner

Convertible Note in 2023
Medical Devices Corner is a company focused on developing innovative medical devices aimed at enhancing cancer diagnosis and treatment. Their primary offering is a novel robotic system designed to facilitate minimally invasive surgeries. By advancing device technology, the company supports healthcare professionals in performing procedures that include biopsies and ablations with reduced invasiveness. Through its commitment to improving surgical techniques, Medical Devices Corner plays a crucial role in the health industry, striving to enhance patient outcomes and streamline medical processes.

Moirai Biodesign

Seed Round in 2023
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

DIA

Grant in 2023
Dia has invented an electrochemical sensor that can measure a wide variety of chemical biomarkers non-invasively in saliva or sweat. The data is sent via Bluetooth to an app on the user’s smartphone and analyzed in real-time. From the app, it can be securely sent to a third party. To date, we have measured hormones, electrolytes, neurotransmitters and metabolites. At DIA, we let the biology dictate which analyte we put on which platform – our wearable arm sleeve for sweat or our table-top device for saliva – because some biomarkers, such as cortisol fluctuate throughout the day and need to be monitored through a wearable sensor, while others, such as creatinine are more suitable to a daily saliva test.

Japet

Convertible Note in 2023
Japet Medical Devices is a French biomedical company focused on developing innovative robotic equipment aimed at enhancing treatment quality. The company specializes in wearable robotic exoskeletons that integrate medical and robotic technologies to assist with both occupational and daily health needs. These exoskeletons are designed to restore balance and facilitate free movement, offering pain relief through orthotic support. Japet's commitment to creating user-friendly solutions reflects its belief in the transformative potential of these technologies to improve the quality of life for many individuals.

VisusNano

Seed Round in 2023
VisusNano Ltd. is a pre-clinical company based in London, United Kingdom, focused on developing a drug-eluting intraocular lens implant for cataract surgery. Founded in 2016, the company aims to enhance patient outcomes by reducing the risks associated with cataract procedures, such as intraocular inflammation, infection, and opacification. This innovative lens technology eliminates the need for postoperative eye drops and laser treatments, positioning it as a potential game-changer in both human and veterinary cataract surgery markets. Through its advancements, VisusNano seeks to revolutionize the standard of care in ophthalmic procedures.

QV Bioelectronics

Seed Round in 2023
QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

Lief Therapeutics

Convertible Note in 2022
Lief Therapeutics is a medical device company focused on improving at-home care for individuals suffering from post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet biosensing patch that measures heart rate and breathing patterns with medical accuracy. This wearable device, known as Lief, helps users manage their stress responses through biofeedback exercises, allowing them to monitor their emotions and behaviors in real-time. Additionally, the device provides clinicians with insights into patient progress, enabling in-session training and tracking of psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, facilitating the tracking of daily progress and personalized practice exercises. Founded in 2014 and based in San Francisco, California, the company sells its products online.

Sava

Series A in 2022
Sava is a company focused on advancing biosensing technology to enhance personal health monitoring. By providing real-time feedback on the body's molecular signature, particularly for athletes, Sava's technology allows for continuous and effortless monitoring of crucial metrics such as glucose and lactate levels. This capability enables athletes to train more effectively, predict fatigue, and optimize their dietary plans. Sava's innovative approach aims to make health information more accessible, delivering insights in a painless and affordable manner, thereby redefining how individuals interact with their health.

Aluna

Series B in 2022
Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

Flore by Sun Genomics

Series B in 2022
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

BioSapien

Series A in 2022
BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Flore by Sun Genomics

Convertible Note in 2022
Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Melio

Seed Round in 2022
Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Moirai Biodesign

Convertible Note in 2022
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Impedans

Series B in 2022
Impedans specializes in intelligent sensing platforms for radio-frequency (RF) and plasma process monitoring. Their technology is utilized across various sectors, including semiconductor manufacturing, vacuum coating, medical devices, hard disk production, and aerospace, among others. The company's products support applications such as fundamental research, process development, tool design, process control, and fault detection and classification. By offering high-resolution plasma diagnostics and quality performance, Impedans enables clients to obtain accurate process measurements and address complex processing challenges effectively. Their expertise in RF and plasma systems, combined with internet-enabled sensing capabilities, provides an independent diagnosis of process health, helping customers optimize their operations.

Kinexcs

Convertible Note in 2022
Kinexcs is an AI-driven health platform and wearables company focused on enhancing mobility and improving quality of life for individuals with musculoskeletal conditions. It addresses issues of incomplete recovery and patient compliance through its innovative digital therapy solutions, which are both cost-effective and convenient. The company has developed KIMIA, the world's first continuous knee health monitor, combined with an AI-based digital therapist that facilitates access to therapy. Kinexcs collaborates with key opinion leaders and major public hospitals in Singapore on various clinical projects, while also offering its products through orthopedic surgeons and significant implant manufacturers. The integration of continuous monitoring and real-time exercise guidance supports patients in managing their conditions effectively.

Pregenerate

Convertible Note in 2022
Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

FluidAI

Seed Round in 2022
FluidAI Medical is a company dedicated to enhancing patient care through innovative technology in post-operative recovery. It has developed a smart catheter system that employs artificial intelligence to monitor patients' health data within the body. This proactive approach enables the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. By leveraging data-driven insights, FluidAI aims to improve recovery outcomes and transform the standards of post-operative care.

QV Bioelectronics

Seed Round in 2022
QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

Artyc

Convertible Note in 2022
Artyc specializes in providing sustainable cold shipping solutions for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers designed to decarbonize the cold chain, thereby fostering a more sustainable logistics industry. By utilizing these innovative containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring throughout their logistics operations, ensuring the safe and efficient transport of temperature-sensitive goods.

Artyc

Seed Round in 2022
Artyc specializes in providing sustainable cold shipping solutions for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers designed to decarbonize the cold chain, thereby fostering a more sustainable logistics industry. By utilizing these innovative containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring throughout their logistics operations, ensuring the safe and efficient transport of temperature-sensitive goods.

Portable Diagnostic Systems

Seed Round in 2022
Portable Diagnostic Systems is focused on developing a microfluidics-based drug testing platform tailored for law enforcement applications. Founded in August 2019, the company aims to enhance roadside drug screening by providing accurate results from a small saliva sample. This innovative approach employs salivary diagnostics and antibody engineering, allowing for quick and easy collection during traffic stops. The platform is designed to minimize false positives and meet the specific needs of police departments, thereby improving the reliability of drug testing in impaired driving cases.

Kalia Health

Convertible Note in 2022
Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, that focuses on enhancing maternal health outcomes. Founded in 2019, the company has developed a home-based early detection test specifically aimed at identifying preeclampsia, a potentially severe pregnancy complication. Their product includes a low-cost and reliable detection strip that allows mothers to self-screen for preeclampsia periodically. This innovation is designed to improve accessibility to early diagnosis, enabling women to seek timely medical care and mitigate the risks associated with this condition. Kalia Health's commitment to safe and affordable maternal health solutions positions it as a valuable contributor to improving health outcomes for expectant mothers.

Zennea Technologies

Convertible Note in 2022
Zennea Technologies is a medical device company based in Surrey, Canada, specializing in the development of therapeutic wearables aimed at reducing snoring and improving overall health through enhanced sleep quality. The company's flagship product, ZENS, is a comfortable and discreet wearable designed to address chronic snoring and mild obstructive sleep apnea at its source. Zennea conducts clinical trials to validate the effectiveness of its technology, which not only targets snoring but also tracks sleep quality, assisting users in making informed decisions to enhance their sleep health.

Conan MedTech

Convertible Note in 2022
Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Conan MedTech

Seed Round in 2022
Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Kalia Health

Seed Round in 2022
Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, that focuses on enhancing maternal health outcomes. Founded in 2019, the company has developed a home-based early detection test specifically aimed at identifying preeclampsia, a potentially severe pregnancy complication. Their product includes a low-cost and reliable detection strip that allows mothers to self-screen for preeclampsia periodically. This innovation is designed to improve accessibility to early diagnosis, enabling women to seek timely medical care and mitigate the risks associated with this condition. Kalia Health's commitment to safe and affordable maternal health solutions positions it as a valuable contributor to improving health outcomes for expectant mothers.

Harae Dx

Convertible Note in 2022
Harae Dx Corp. is a medical diagnostics company specializing in cancer detection. The company has created an automated, portable system that facilitates early cancer diagnosis by identifying cancer biomarkers directly, eliminating the need to send samples to third-party laboratories. This innovative approach reduces the risk of human error in processing and enhances the speed of results, allowing healthcare professionals to detect and treat cancer more effectively and affordably. Harae Dx's compact and cost-efficient solution aims to improve patient outcomes through timely and accurate diagnostics.

FeetMe

Convertible Note in 2022
FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.

QuantumCyte

Convertible Note in 2022
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Leadoptik

Angel Round in 2022
Leadoptik is a deep-tech company focused on developing advanced miniature imaging technology designed for minimally invasive medical procedures. Its platform enhances surgical capabilities by providing high-resolution imaging and 3D navigation in real time, allowing surgeons to visualize small anatomical structures with greater clarity than existing imaging systems. This innovative approach facilitates the early detection of cancer and improves the overall effectiveness of surgical interventions, ultimately contributing to better patient outcomes.

CroíValve

Series A in 2022
CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Chronus Health

Series A in 2022
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Cellens

Seed Round in 2022
Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

Cellens

Convertible Note in 2022
Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

Hydrostasis

Convertible Note in 2021
Hydrostasis is a company based in San Diego, California, that specializes in developing hydration monitoring systems tailored for athletes. Its technology includes wearable sensors that assess individual hydration needs based on body composition, providing personalized and clinical-grade accuracy. The system offers real-time notifications to alert athletes before dehydration affects their performance. In addition to serving athletes, Hydrostasis collaborates with device manufacturers for both consumer and clinical applications, enhancing hydration monitoring capabilities across various platforms. By leveraging scientific methodologies and cloud-based data storage, Hydrostasis aims to empower athletes to optimize their hydration levels, ultimately supporting their physical and mental performance.

Haptic (WearWorks)

Convertible Note in 2021
Haptic (WearWorks), a B2B SaaS company creating a universal language through touch. We have patented the haptic navigation technology, which made history. Haptic guided the first runner who is blind in the NYC Marathon with their HapticNav app. Haptic is redefining inclusive mobility. Our patented technology uses tactile communication to guide users through subtle vibrations, offering a seamless, screen-free, ears-free experience. This empowers all users—especially those with visual impairments—to navigate independently. Haptic is revolutionizing inclusive technology. Our patented HapticNav tool transforms how we navigate the world, offering a hands-free, eyes-free experience through the power of touch. It empowers thousands, especially those with visual impairments, to reclaim their independence and live screen-free.

XN Health

Seed Round in 2021
XN Health is a medical device company based in Texas, founded in 2021. The company specializes in developing healthcare devices aimed at improving the process of mechanical ventilation. Its innovative technology focuses on phrenic nerve stimulation, which induces diaphragm contractions during ventilation. This approach helps protect against diaphragm dysfunction in patients who are mechanically ventilated, ultimately enabling them to wean off the ventilator more quickly and safely.

Criam

Seed Round in 2021
Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device designed for blood type analysis and the detection of infectious diseases. The company's flagship product offers rapid and accurate testing for various conditions, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. This portable device operates independently of electricity or laboratory infrastructure, making it accessible for use in diverse environments. Additionally, Criam's technology is scalable, allowing a single reader to perform multiple tests using specific cartridges and advanced computer vision algorithms. By optimizing blood testing services, Criam aims to provide timely health information and improve clinical decision-making.

BioSapien

Seed Round in 2021
BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Impedans

Series B in 2021
Impedans specializes in intelligent sensing platforms for radio-frequency (RF) and plasma process monitoring. Their technology is utilized across various sectors, including semiconductor manufacturing, vacuum coating, medical devices, hard disk production, and aerospace, among others. The company's products support applications such as fundamental research, process development, tool design, process control, and fault detection and classification. By offering high-resolution plasma diagnostics and quality performance, Impedans enables clients to obtain accurate process measurements and address complex processing challenges effectively. Their expertise in RF and plasma systems, combined with internet-enabled sensing capabilities, provides an independent diagnosis of process health, helping customers optimize their operations.

Ostoform

Series A in 2021
Ostoform Limited is a medical device company based in Dublin, Ireland, focused on improving skin health for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform develops patented technologies aimed at managing and reducing skin complications associated with ostomies. The company's primary products include a mouldable seal that fits securely around the stoma and FLOWASSIST, which directs stoma output away from the skin. By effectively guiding the corrosive output into the ostomy bag, these products help prevent skin irritation and swelling, enhancing patient comfort and quality of life. Ostoform aims to become a global leader in the ostomy skin health market, leveraging its innovative solutions to address the needs of ostomy patients.

Kegg

Seed Round in 2021
Kegg is a fertility tracking device that combines the functions of monitoring vaginal fluid and facilitating pelvic floor exercises. Founded in 2017 and based in San Francisco, California, Kegg utilizes advanced sensing technology to detect changes in cervical fluid, thereby enabling women to identify their fertile window and ovulation up to seven days in advance. This innovative approach provides essential data that enhances the diagnosis, monitoring, and treatment of women's reproductive health, significantly increasing the chances of natural conception. By offering an intuitive and effective solution, Kegg empowers women with the information they need to make informed decisions regarding their fertility.

Circadia Health

Series A in 2021
Circadia Health specializes in developing AI-powered, FDA-approved contactless patient monitoring systems aimed at enhancing clinical outcomes. The technology enables the detection of respiratory complications from up to eight feet away, eliminating the need for physical devices on the patient or bed. By continuously monitoring respiratory rates, Circadia's system allows clinicians to predict medical events such as congestive heart failure, pneumonia, and sepsis, often hours or days in advance. A team of virtual nurses analyzes device data in conjunction with patients' electronic health records to provide personalized, predictive risk alerts around the clock. This innovative approach not only facilitates remote assessments but also aims to reduce healthcare costs while improving patient care across various settings, from hospitals to home environments.

RizLab Health

Convertible Note in 2021
Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

RizLab Health

Seed Round in 2021
Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.

Strados Labs

Seed Round in 2021
Strados Labs, LLC is a medical technology company based in Philadelphia, Pennsylvania, that focuses on innovating respiratory health management through advanced biosensors and artificial intelligence. Founded in 2016, Strados Labs develops a wearable device that provides real-time insights into respiratory metrics such as breathing speed, sounds, and patterns. This device is equipped with a continuous breathing sensor that enables remote monitoring of patients with respiratory conditions like asthma and chronic obstructive pulmonary disease. By connecting the device to a mobile application, patients and healthcare providers can access critical respiratory data, facilitating informed decision-making and improved management of respiratory health.

Japet

Seed Round in 2021
Japet Medical Devices is a French biomedical company focused on developing innovative robotic equipment aimed at enhancing treatment quality. The company specializes in wearable robotic exoskeletons that integrate medical and robotic technologies to assist with both occupational and daily health needs. These exoskeletons are designed to restore balance and facilitate free movement, offering pain relief through orthotic support. Japet's commitment to creating user-friendly solutions reflects its belief in the transformative potential of these technologies to improve the quality of life for many individuals.

QV Bioelectronics

Seed Round in 2021
QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

QuantumCyte

Convertible Note in 2021
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Jointechlabs

Pre Seed Round in 2021
JointechLabs, Inc. is a company that specializes in point-of-care regenerative medicine therapies, headquartered in Brandon, Florida. The organization develops innovative medical devices, including the MiniTC® for the United States and the Mini-Stem System® for international markets. These devices facilitate the processing of autologous body fat, enabling safe and efficient use in non-surgical orthopedic and aesthetic procedures within medical offices. By providing a closed-loop disposable system for human tissue processing, JointechLabs simplifies the creation of high-quality injectable fat grafts and fat-derived stem cells, making individualized cell and tissue-based therapies more accessible and cost-effective for hospitals and clinics. Additionally, the company is expanding its product pipeline to include biologic drugs and 3D bioprinted products aimed at orthopedic, wound healing, and plastic and reconstructive surgery applications.

Pregenerate

Seed Round in 2021
Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

XXICO

Seed Round in 2021
XXICO is a platform consisting of devices and software that enable remote health monitoring.

FluidAI

Seed Round in 2021
FluidAI Medical is a company dedicated to enhancing patient care through innovative technology in post-operative recovery. It has developed a smart catheter system that employs artificial intelligence to monitor patients' health data within the body. This proactive approach enables the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. By leveraging data-driven insights, FluidAI aims to improve recovery outcomes and transform the standards of post-operative care.

Harae Dx

Seed Round in 2021
Harae Dx Corp. is a medical diagnostics company specializing in cancer detection. The company has created an automated, portable system that facilitates early cancer diagnosis by identifying cancer biomarkers directly, eliminating the need to send samples to third-party laboratories. This innovative approach reduces the risk of human error in processing and enhances the speed of results, allowing healthcare professionals to detect and treat cancer more effectively and affordably. Harae Dx's compact and cost-efficient solution aims to improve patient outcomes through timely and accurate diagnostics.

DeepSpin

Convertible Note in 2021
DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in developing artificial intelligence-powered magnetic resonance imaging (MRI) equipment. The company’s innovative technology aims to provide MRI imaging systems that are significantly smaller, lighter, and more cost-effective than traditional models. By leveraging generative topological design and deep learning techniques, DeepSpin's MRI machines enhance accessibility to medical imaging, making it available to a wider range of patients globally. This approach seeks to improve healthcare standards in various medical fields previously lacking adequate imaging solutions.

Medical Devices Corner

Seed Round in 2021
Medical Devices Corner is a company focused on developing innovative medical devices aimed at enhancing cancer diagnosis and treatment. Their primary offering is a novel robotic system designed to facilitate minimally invasive surgeries. By advancing device technology, the company supports healthcare professionals in performing procedures that include biopsies and ablations with reduced invasiveness. Through its commitment to improving surgical techniques, Medical Devices Corner plays a crucial role in the health industry, striving to enhance patient outcomes and streamline medical processes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.